Neovii is a Swiss company whose anti-T-lymphocyte globulin, Grafalon, is given before stem cell transplants to lower the risk of graft versus host disease.
Neovii, headquartered in Rapperswil-Jona, Switzerland, makes Grafalon (anti-T-lymphocyte globulin, previously ATG-Fresenius), a rabbit-derived polyclonal antibody used in conditioning before allogeneic haematopoietic stem cell transplantation to reduce graft versus host disease and rejection. It has led phase 3 transplant trials in leukaemia registered on ClinicalTrials.gov.
Shares Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer, Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy.
Shares Allogeneic stem cell transplant (allo-SCT), Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Shares Allogeneic stem cell transplantation, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Shares Allogeneic stem cell transplantation, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Shares Allogeneic stem cell transplantation, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Shares Allogeneic stem cell transplantation, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Shares Allogeneic stem cell transplantation, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Shares Allogeneic stem cell transplantation, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/